Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Advocates claim Gilead and others unfairly limited competition for HIV combination pills.
Researchers have called for revised treatment guidelines to address the higher risk of fracture in the HIV population.
This finding from a study of people switching from TDF to TAF for HIV treatment may also have implications for those on PrEP.
The newer tenofovir formulation can raise cholesterol and triglyceride levels, but these changes are reversible.
Swiss researchers analyzed shifts in kidney function among those switching from the old form of the HIV medication to the new one.
Tenofovir disoproxil fumarate is found in Truvada, Viread, Atripla, Complera and Stribild.
Gilead has based its entire HIV drug portfolio on updating tenofovir, ostensibly to make it safer for bones and kidneys.
Nevertheless, researchers advise careful kidney monitoring when pairing the medications.
In a recent study, Edurant was better tolerated and less toxic and led to fewer discontinuations.
That’s compared with HIV-negative men.
A new analysis finds that Gilead Sciences’ updated version of its key antiretroviral tenofovir may not actually offer any safety benefits.
Largest-ever analysis of bone loss in the HIV population found that treating hep C, taking vitamin D and exercising might be preventive.
People with HIV taking Viread, especially if combined with Norvir, should receive regular kidney monitoring.
Increases may be designed to push patients to the company’s newer regimens.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.